DK1135139T3 - Præparater indeholdende mikroniseret eplerenon - Google Patents
Præparater indeholdende mikroniseret eplerenonInfo
- Publication number
- DK1135139T3 DK1135139T3 DK99963052T DK99963052T DK1135139T3 DK 1135139 T3 DK1135139 T3 DK 1135139T3 DK 99963052 T DK99963052 T DK 99963052T DK 99963052 T DK99963052 T DK 99963052T DK 1135139 T3 DK1135139 T3 DK 1135139T3
- Authority
- DK
- Denmark
- Prior art keywords
- preparations containing
- containing micronized
- micronized eplerenone
- eplerenone
- preparations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11164698P | 1998-12-09 | 1998-12-09 | |
PCT/US1999/029136 WO2000033847A1 (fr) | 1998-12-09 | 1999-12-08 | Compositions d'eplerenone microfine |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1135139T3 true DK1135139T3 (da) | 2004-01-05 |
Family
ID=22339668
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK99963052T DK1135139T3 (da) | 1998-12-09 | 1999-12-08 | Præparater indeholdende mikroniseret eplerenon |
Country Status (30)
Country | Link |
---|---|
US (7) | US6410054B1 (fr) |
EP (1) | EP1135139B1 (fr) |
JP (1) | JP2002531508A (fr) |
KR (1) | KR100671275B1 (fr) |
CN (1) | CN1230179C (fr) |
AR (1) | AR028982A1 (fr) |
AT (1) | ATE249223T1 (fr) |
AU (1) | AU763166B2 (fr) |
BR (1) | BR9915964A (fr) |
CA (1) | CA2326842A1 (fr) |
CZ (1) | CZ20011942A3 (fr) |
DE (1) | DE69911240T2 (fr) |
DK (1) | DK1135139T3 (fr) |
EA (1) | EA003266B1 (fr) |
ES (1) | ES2207977T3 (fr) |
HK (1) | HK1041641B (fr) |
HU (1) | HU224428B1 (fr) |
ID (1) | ID30115A (fr) |
IL (1) | IL143301A0 (fr) |
IS (1) | IS2325B (fr) |
MY (1) | MY125651A (fr) |
NO (1) | NO20012782L (fr) |
NZ (1) | NZ511869A (fr) |
PL (1) | PL198425B1 (fr) |
PT (1) | PT1135139E (fr) |
TR (1) | TR200101643T2 (fr) |
TW (1) | TWI234459B (fr) |
UA (1) | UA74141C2 (fr) |
WO (1) | WO2000033847A1 (fr) |
ZA (1) | ZA200104361B (fr) |
Families Citing this family (93)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA74141C2 (uk) * | 1998-12-09 | 2005-11-15 | Дж.Д. Сірл Енд Ко. | Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти) |
EP1527782A1 (fr) * | 1999-12-08 | 2005-05-04 | Pharmacia Corporation | Compositions nanoparticulaires d'eplérenone |
DE60019741T2 (de) * | 1999-12-08 | 2006-03-02 | Pharmacia Corp., Chicago | Nanopartikelzusammensetzungen enthaltend eplerenon |
CA2409437A1 (fr) * | 2000-05-11 | 2001-11-22 | Pharmacia Corporation | Composition antagoniste de l'aldosterone destinee a etre liberee durant l'acrophase de l'aldosterone |
JP2004518611A (ja) * | 2000-07-27 | 2004-06-24 | ファルマシア・コーポレーション | 炎症関連障害を予防するか又は治療するためのアルドステロン遮断薬療法 |
AU7905001A (en) * | 2000-07-27 | 2002-02-13 | Pharmacia Corp | Epoxy-steroidal aldosterone antagonist and beta-adrenergic antagonist combination therapy for treatment of congestive heart failure |
AU2001285318A1 (en) * | 2000-08-28 | 2002-03-13 | Pharmacia Corporation | Use of an aldosterone receptor antagonist to improve cognitive function |
US8168616B1 (en) * | 2000-11-17 | 2012-05-01 | Novartis Ag | Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension |
ATE303399T1 (de) | 2001-03-12 | 2005-09-15 | Intercept Pharmaceuticals Inc | Steroide als agonisten für fxr |
US20040173147A1 (en) * | 2001-06-07 | 2004-09-09 | Figueroa Iddys D. | Application of a bioactive agent to a delivery substrate |
US20040173146A1 (en) * | 2001-06-07 | 2004-09-09 | Figueroa Iddys D. | Application of a bioactive agent to a delivery substrate |
US6962715B2 (en) * | 2001-10-24 | 2005-11-08 | Hewlett-Packard Development Company, L.P. | Method and dosage form for dispensing a bioactive substance |
GB0114532D0 (en) * | 2001-06-14 | 2001-08-08 | Jagotec Ag | Novel compositions |
UA76475C2 (en) * | 2001-07-19 | 2006-08-15 | Pharmacia Corp | Combination of eplerenon and hmg co-a reductase inhibitor and its use for treatment and/or prophylaxis of pathologic condition in cardiovascular system |
WO2003051372A1 (fr) * | 2001-12-13 | 2003-06-26 | Pharmacia Corporation | Methodes destinees a traiter ou prevenir des effets pathogenes induits par l'aldosterone chez un sujet au moyen d'un antagoniste d'aldosterone epoxy-steroidien |
JP2005521665A (ja) * | 2002-01-30 | 2005-07-21 | ファルマシア・コーポレーション | 心血管障害の予防および治療のための、アルドステロンアンタゴニストおよび非ステロイド系抗炎症剤の併用治療 |
WO2003072139A1 (fr) * | 2002-02-26 | 2003-09-04 | Astrazeneca Ab | Formulation pharmaceutique d'iressa comprenant un derive de cellulose soluble dans l'eau |
AU2003225871A1 (en) * | 2002-03-20 | 2003-10-08 | Pharmacia Corporation | Storage stable eplerenone formulation |
US7235655B2 (en) * | 2002-03-22 | 2007-06-26 | Pharmacia & Upjohn Company | Processes to prepare eplerenone |
KR20040104632A (ko) * | 2002-04-26 | 2004-12-10 | 쉐링 악티엔게젤샤프트 | 호르몬 대체 요법을 받는 여성에서 고혈압의 치료 |
JP2005536536A (ja) * | 2002-08-23 | 2005-12-02 | ファルマシア コーポレイション | アルドステロンブロッカーによるマトリックスメタロプロテイナーゼ(mmp)活性のモジュレーション |
AU2003279070A1 (en) * | 2002-09-30 | 2004-04-23 | Acusphere Inc | Sustained release porous microparticles for inhalation |
AU2002368326A1 (en) * | 2002-11-05 | 2004-06-07 | Schering Aktiengesellschaft | Hormone replacement therapy with drospirenone |
US7786101B2 (en) * | 2002-11-05 | 2010-08-31 | Bayer Schering Pharma Ag | Cardiovascular protection using anti-aldosteronic progestins |
ES2338781T3 (es) * | 2002-11-05 | 2010-05-12 | Bayer Schering Pharma Aktiengesellschaft | Uso de la drospirenona para el tratamiento de una hipertension. |
EP1569623B1 (fr) * | 2002-12-13 | 2008-10-15 | Jagotec Ag | Preparation topique de spironolactone nanoparticulaire |
DE10335027A1 (de) | 2003-07-31 | 2005-02-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung von Angiotensin II Rezeptor Antagonisten |
US20040229901A1 (en) * | 2003-02-24 | 2004-11-18 | Lauren Otsuki | Method of treatment of disease using an adenosine A1 receptor antagonist |
TW200500070A (en) * | 2003-04-25 | 2005-01-01 | Novacardia Inc | Method of improved diuresis in individuals with impaired renal function |
US20060293312A1 (en) * | 2003-04-25 | 2006-12-28 | Howard Dittrich | Method of improved diuresis in individuals with impaired renal function |
KR100473422B1 (ko) * | 2003-06-12 | 2005-03-14 | 박원봉 | 렉틴 함유 천연물의 장용성 코팅용 조성물 |
CA2675724C (fr) * | 2003-06-16 | 2012-12-04 | Andrx Pharmaceuticals, Llc | Composition orale a liberation prolongee |
US7198653B2 (en) | 2003-07-31 | 2007-04-03 | Delavau Llc | Calcium carbonate granulation |
US20050031683A1 (en) * | 2003-08-04 | 2005-02-10 | Ashish Kapoor | Solid pharmaceutical composition |
US7390503B1 (en) | 2003-08-22 | 2008-06-24 | Barr Laboratories, Inc. | Ondansetron orally disintegrating tablets |
US7282217B1 (en) * | 2003-08-29 | 2007-10-16 | Kv Pharmaceutical Company | Rapidly disintegrable tablets |
HUE044279T2 (hu) * | 2003-09-12 | 2019-10-28 | Amgen Inc | Cinakalcet HCl gyors feloldódású készítménye |
US20050069591A1 (en) * | 2003-09-30 | 2005-03-31 | Howard Bernstein | Injectable, oral, or topical sustained release pharmaceutical formulations |
US20050203482A1 (en) * | 2004-03-15 | 2005-09-15 | Chinea Vanessa I. | Pharmaceutical dispensing apparatus and method |
US20070196471A1 (en) * | 2004-04-02 | 2007-08-23 | Thosar Shilpa S | Micronized Eplerenone Compositions |
US20050232957A1 (en) * | 2004-04-14 | 2005-10-20 | Katz Kenneth A | Compositions and methods for moisturizing skin |
AU2005237466A1 (en) * | 2004-04-16 | 2005-11-10 | Novacardia, Inc. | Combination therapy comprising an adenosine A1 receptor antagonist and an aldosterone inhibitor |
US8075910B2 (en) * | 2004-05-20 | 2011-12-13 | Pbm Pharmaceuticals, Inc. | Oral compositions comprising edible oils and vitamins and/or minerals and methods for making oral compositions |
US7846466B2 (en) * | 2004-06-10 | 2010-12-07 | Northwestern University | Biodegradable scaffolds and uses thereof |
US20060134212A1 (en) * | 2004-09-02 | 2006-06-22 | Forest Laboratories, Inc. | Lercanidipine immediate release compositions |
US20060165788A1 (en) * | 2004-09-09 | 2006-07-27 | Wattanaporn Abramowitz | Lercanidipine pH dependent pulsatile release compositions |
US20060165789A1 (en) * | 2004-09-09 | 2006-07-27 | Forest Laboratories, Inc. | Lercanidipine modified release compositions |
US8022053B2 (en) * | 2004-11-02 | 2011-09-20 | Bayer Schering Pharma Aktiengesellschaft | Oral solid dosage forms containing a low dose of estradiol |
CA2585003C (fr) * | 2004-11-23 | 2010-08-17 | Dong Wha Pharm. Ind. Co., Ltd. | Preparation orale presentant une biodisponibilite amelioree |
WO2006097342A1 (fr) * | 2005-03-17 | 2006-09-21 | Synthon B.V. | Procede de preparation de composes steroides |
US20060252738A1 (en) * | 2005-05-06 | 2006-11-09 | Phero Tech Inc. | Method for preparing and using water-based steroid pheromone compositions |
WO2006125304A1 (fr) * | 2005-05-25 | 2006-11-30 | Liponex, Inc. | Compositions pharmaceutiques pour traiter ou prevenir une maladie coronarienne |
WO2007012960A1 (fr) * | 2005-07-29 | 2007-02-01 | Glenmark Pharmaceuticals Limited | Compositions pharmaceutiques à base d’éplérénone |
US20070095705A1 (en) * | 2005-10-31 | 2007-05-03 | Legault Dennis X | Array of packages |
EP2672266B1 (fr) * | 2006-01-13 | 2018-08-01 | Indiana University Research & Technology Corporation | Méthode de sélection d'un candidat à la transplantation pulmonaire pour un risque élevé de rejet |
US20070184163A1 (en) * | 2006-02-07 | 2007-08-09 | International Flavors, & Fragrances Inc. | Non-hygroscopic flavor particles |
US20090175934A1 (en) * | 2006-03-08 | 2009-07-09 | Jubilant Organosys Ltd. | Extended Release Pharmaceutical Formulation of Venlafaxine and Method of Manufacturing the Same |
US20070248665A1 (en) * | 2006-04-24 | 2007-10-25 | Sherman Bernard C | Compositions comprising co-precipitate of eplerenone and a water-soluble excipient |
JP2009538912A (ja) * | 2006-05-31 | 2009-11-12 | バーテックス ファーマシューティカルズ インコーポレイテッド | インターロイキン−1β変換酵素阻害剤の経口制御放出剤形 |
JP2009540003A (ja) * | 2006-06-16 | 2009-11-19 | ノヴァカーディア,インク. | Aa1raの低頻度投与を含む腎機能の長期間にわたる改善 |
DE102006033723A1 (de) * | 2006-07-21 | 2008-01-24 | Bayer Technology Services Gmbh | Formulierungen von Multikompartimenten-Granulaten für Wirkstoffe |
EP2051696A2 (fr) * | 2006-08-18 | 2009-04-29 | Morton Grove Pharmaceuticals, Inc. | Compositions liquides stables de lévétiracétam et procédés |
US9138414B1 (en) | 2006-09-15 | 2015-09-22 | Delavau Llc | Calcium supplement having enhanced absorption |
AU2007335192A1 (en) * | 2006-12-21 | 2008-06-26 | Alphapharm Pty Ltd | Pharmaceutical composition |
WO2008089549A1 (fr) | 2007-01-22 | 2008-07-31 | Genpharm Ulc | Compositions pharmaceutiques comprenant du nébivolol ou un analogue du nébivolol |
EP2124901B1 (fr) | 2007-02-01 | 2017-07-19 | Takeda Pharmaceutical Company Limited | Préparation de comprimé ne provoquant pas de problème de pastillage |
WO2008121882A1 (fr) * | 2007-03-29 | 2008-10-09 | Novacardia, Inc. | Procédés améliorés d'administration d'antagonistes de récepteur d'adénosine a1 |
WO2008121893A1 (fr) * | 2007-03-29 | 2008-10-09 | Novacardia, Inc. | Procédés de traitement d'insuffisance cardiaque et de dysfonctionnement rénal chez des individus avec un antagoniste de récepteur a1 de l'adénosine |
US8372431B2 (en) * | 2007-10-26 | 2013-02-12 | Bial-Portela & C.A., S.A. | Pharmaceutical composition comprising licarbazepine acetate |
WO2009114226A1 (fr) * | 2008-03-11 | 2009-09-17 | Mallinckrodt Inc. | Utilisation de stéarate de magnésium dihydraté pour la lubrification de compositions pharmaceutiques solides |
US8343524B2 (en) * | 2008-07-31 | 2013-01-01 | Clarke Mosquito Control Products, Inc. | Extended release tablet and method for making and using same |
GB0814953D0 (en) * | 2008-08-18 | 2008-09-24 | Unilever Plc | Improvements relating to nanodisperse compositions |
US8545892B2 (en) | 2009-06-26 | 2013-10-01 | Nano Pharmaceutical Laboratories, Llc | Sustained release beads and suspensions including the same for sustained delivery of active ingredients |
US8968456B2 (en) * | 2009-08-28 | 2015-03-03 | Hercules Incorporated | Film coating composition from solid powder hydrophobic compounds |
US9345848B2 (en) | 2009-10-20 | 2016-05-24 | Sima Patent Ve Lisanslama Hizmetleri Ltd. Sti. | Dry powder inhaler |
WO2011076749A2 (fr) | 2009-12-23 | 2011-06-30 | Ratiopharm Gmbh | Forme solide de dosage pharmaceutique |
WO2011076412A1 (fr) * | 2009-12-23 | 2011-06-30 | Ratiopharm Gmbh | Forme d'administration orale contenant de l'entecavir |
TW201206502A (en) * | 2010-06-16 | 2012-02-16 | Teijin Pharma Ltd | Controlled release nucleated tablet |
TR201007653A2 (tr) * | 2010-09-20 | 2012-04-24 | Bi̇lgi̇ç Mahmut | Eplerenon içeren farmasötik kompozisyon |
KR20120093461A (ko) * | 2011-01-27 | 2012-08-23 | 양지화학 주식회사 | 정제형 감미료 조성물 및 그 제조방법 |
EA026450B1 (ru) | 2011-11-25 | 2017-04-28 | Махмут Билджик | Ингалятор |
WO2013149258A2 (fr) | 2012-03-30 | 2013-10-03 | Charles Drew University of Medicine and Science | Compositions et procédés de traitement ou de prévention de troubles du syndrome métabolique |
KR20200017549A (ko) | 2012-06-04 | 2020-02-18 | 파마싸이클릭스 엘엘씨 | 브루톤 타이로신 키나아제 저해제의 결정 형태 |
FR3001890B1 (fr) * | 2013-02-08 | 2015-08-07 | Greenpharma Sas | Composition dermatologique pour repousse des poils ou des cheveux |
US20140271923A1 (en) | 2013-03-14 | 2014-09-18 | Christopher Brian Reid | Compositions & formulations for preventing and treating chronic diseases that cluster in patients such as cardiovascular disease, diabetes, obesity, polycystic ovary syndrome, hyperlipidemia and hypertension, as well as for preventing and treating other diseases and conditions |
USD744087S1 (en) | 2013-10-01 | 2015-11-24 | Mahmut Bilgic | Dry powder inhaler |
US11007203B2 (en) * | 2013-10-06 | 2021-05-18 | Salim Shah | Formulations comprising aldosterone receptor antagonists and treatments using same |
US10716783B2 (en) | 2013-12-12 | 2020-07-21 | Cornell University | Prolylhydroxylase/ATF4 inhibitors and methods of use for treating neural cell injury or death and conditions resulting therefrom |
FR3019045A1 (fr) * | 2014-03-26 | 2015-10-02 | Greenpharma Sas | Composition dermatologique pour la repousse des poils ou des cheveux |
MX2017001671A (es) | 2014-08-07 | 2017-07-04 | Pharmacyclics Llc | Formulaciones novedosas de un inhibidor de la tirosina cinasa de bruton. |
WO2016063269A1 (fr) | 2014-10-20 | 2016-04-28 | Prendergast Patrick T | Utilisation d'antagonistes au récepteur stéroïdien nucléaire, seuls ou en association, comme agents antiviraux directs pour inhiber des alphavirus, togavirus, filovirus, arénavirus, bunyavirus, flavivirus et rhabdovirus |
EP3244881A4 (fr) | 2015-01-12 | 2018-08-15 | Nano Pharmaceutical Laboratories LLC | Microbilles multicouches à libération prolongée et leur procédés de fabrication |
NZ734446A (en) | 2015-03-03 | 2022-12-23 | Pharmacyclics Llc | Pharmaceutical formulations of bruton’s tyrosine kinase inhibtor |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4082751A (en) * | 1976-02-13 | 1978-04-04 | Bristol-Myers Company | Therapeutic agents |
IT1130924B (it) * | 1980-03-06 | 1986-06-18 | Secifarma Spa | Procedimento per la preparazione di spironolattone micronizzato |
FI77669C (fi) * | 1983-04-13 | 1989-04-10 | Ciba Geigy Ag | 20-spiroxaner och analoger, som innehaoller en oeppen ring e, foerfarande foer deras framstaellning samt dessa innehaollande farmaceutiska preparat. |
US5082668A (en) | 1983-05-11 | 1992-01-21 | Alza Corporation | Controlled-release system with constant pushing source |
IE58110B1 (en) * | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
US4753802A (en) | 1986-03-19 | 1988-06-28 | Alza Corporation | Verapamil dosage form |
GB8613689D0 (en) * | 1986-06-05 | 1986-07-09 | Euro Celtique Sa | Pharmaceutical composition |
US4847093A (en) | 1986-06-19 | 1989-07-11 | Alza Corporation | Dosage form with means for governing rate of gas formation |
US5057317A (en) | 1987-03-24 | 1991-10-15 | Chugai Seiyaku Kabushiki Kaisha | Slow-release pharmaceutical agent |
GB8717168D0 (en) | 1987-07-21 | 1987-08-26 | Roussel Lab Ltd | Controlled-release device |
NZ238867A (en) | 1990-07-12 | 1993-08-26 | Alza Corp | Dosage form for delayed release comprising pharmaceutically active substance and a drug-release hindering means and a second composition which imbibes fluid, expands, and ejects the active substance from the device |
AU1432292A (en) | 1991-02-07 | 1992-09-07 | Lawrence Samuel Bass | Drug delivery composition and method of using the same |
US5190765A (en) | 1991-06-27 | 1993-03-02 | Alza Corporation | Therapy delayed |
US5160744A (en) | 1991-06-27 | 1992-11-03 | Alza Corporation | Verapmil therapy |
US5529992A (en) * | 1992-04-21 | 1996-06-25 | Curators Of The University Of Missouri | Method for inhibiting myocardial fibrosis by administering an aldosterone antagonist which suppresses aldoster one receptors |
IT1260505B (it) | 1992-06-01 | 1996-04-09 | Poli Ind Chimica Spa | Sistemi farmaceutici orali a cessione ritardata per il rilascio specifico nel colon |
US5324718A (en) * | 1992-07-14 | 1994-06-28 | Thorsteinn Loftsson | Cyclodextrin/drug complexation |
GB9311191D0 (en) | 1993-05-29 | 1993-07-14 | Danbiosyst Uk | Controlled release drug formulation |
AU5692398A (en) | 1996-12-09 | 1998-07-03 | Proscript, Inc. | Substituted 5-amino-1,3,4-thiadiazole-2-thiones |
ES2186017T3 (es) | 1996-12-11 | 2003-05-01 | Searle & Co | Procedimientos para la preparacion de delta 4,5-esteroides 3-ceto-7alfa-alcoxicarbonil-sustituidos y compuestos intermedios de utilidad en los mismos. |
UA74141C2 (uk) * | 1998-12-09 | 2005-11-15 | Дж.Д. Сірл Енд Ко. | Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти) |
DE60019741T2 (de) * | 1999-12-08 | 2006-03-02 | Pharmacia Corp., Chicago | Nanopartikelzusammensetzungen enthaltend eplerenon |
-
1999
- 1999-08-12 UA UA2001063853A patent/UA74141C2/uk unknown
- 1999-12-07 AR ARP990106255A patent/AR028982A1/es not_active Application Discontinuation
- 1999-12-08 EP EP99963052A patent/EP1135139B1/fr not_active Expired - Lifetime
- 1999-12-08 KR KR1020017007041A patent/KR100671275B1/ko not_active IP Right Cessation
- 1999-12-08 IL IL14330199A patent/IL143301A0/xx not_active IP Right Cessation
- 1999-12-08 PL PL349632A patent/PL198425B1/pl not_active IP Right Cessation
- 1999-12-08 ES ES99963052T patent/ES2207977T3/es not_active Expired - Lifetime
- 1999-12-08 DK DK99963052T patent/DK1135139T3/da active
- 1999-12-08 NZ NZ511869A patent/NZ511869A/en unknown
- 1999-12-08 US US09/456,614 patent/US6410054B1/en not_active Expired - Lifetime
- 1999-12-08 JP JP2000586339A patent/JP2002531508A/ja active Pending
- 1999-12-08 MY MYPI99005328A patent/MY125651A/en unknown
- 1999-12-08 CA CA002326842A patent/CA2326842A1/fr not_active Abandoned
- 1999-12-08 WO PCT/US1999/029136 patent/WO2000033847A1/fr active IP Right Grant
- 1999-12-08 HU HU0104718A patent/HU224428B1/hu not_active IP Right Cessation
- 1999-12-08 ID IDW00200101191A patent/ID30115A/id unknown
- 1999-12-08 AT AT99963052T patent/ATE249223T1/de active
- 1999-12-08 CZ CZ20011942A patent/CZ20011942A3/cs unknown
- 1999-12-08 EA EA200100519A patent/EA003266B1/ru not_active IP Right Cessation
- 1999-12-08 TR TR2001/01643T patent/TR200101643T2/xx unknown
- 1999-12-08 AU AU19368/00A patent/AU763166B2/en not_active Expired
- 1999-12-08 PT PT99963052T patent/PT1135139E/pt unknown
- 1999-12-08 BR BR9915964-3A patent/BR9915964A/pt not_active Application Discontinuation
- 1999-12-08 DE DE69911240T patent/DE69911240T2/de not_active Expired - Lifetime
- 1999-12-08 CN CNB998141100A patent/CN1230179C/zh not_active Expired - Fee Related
-
2000
- 2000-02-22 TW TW088121495A patent/TWI234459B/zh not_active IP Right Cessation
-
2001
- 2001-05-25 IS IS5953A patent/IS2325B/is unknown
- 2001-05-28 ZA ZA200104361A patent/ZA200104361B/en unknown
- 2001-06-06 NO NO20012782A patent/NO20012782L/no unknown
-
2002
- 2002-01-31 US US10/066,360 patent/US6592902B2/en not_active Expired - Lifetime
- 2002-03-19 US US10/100,712 patent/US6558707B1/en not_active Expired - Lifetime
- 2002-03-19 US US10/100,930 patent/US6534093B1/en not_active Expired - Lifetime
- 2002-03-19 US US10/101,361 patent/US6495165B1/en not_active Expired - Lifetime
- 2002-04-25 HK HK02103113.4A patent/HK1041641B/zh unknown
- 2002-11-06 US US10/289,025 patent/US6863902B2/en not_active Expired - Fee Related
-
2004
- 2004-04-02 US US10/817,577 patent/US7157101B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1135139T3 (da) | Præparater indeholdende mikroniseret eplerenon | |
DE60019741D1 (de) | Nanopartikelzusammensetzungen enthaltend eplerenon | |
NO20005913L (no) | Legemiddelsammensetning | |
DE69900634T2 (de) | Shampoozusammensetzungen | |
IS5046A (is) | Lyfjasamsetningar | |
IS6040A (is) | Valdekoxib efnablöndur | |
DK0911385T3 (da) | Stanolholdige sammensætninger | |
DK0921796T3 (da) | Tetrahydrolipstatinholdige præparater | |
DE69933200D1 (de) | Kombinierte impfstoffzusammensetzungen | |
DE60020343D1 (de) | Cilostazol enthaltende zubereitung | |
DE69935609D1 (de) | Formulierungen enthaltend cefuroxim-axetil | |
NO990956L (no) | Klorfluorkarbonfrie mometasonfuroataerosolpreparater | |
PT969815E (pt) | Composicoes farmaceuticas | |
ATE298576T1 (de) | Arzneizubereitungen | |
ATE246494T1 (de) | Brausezubereitungen | |
EE200000330A (et) | Farmatseutilised kompositsioonid | |
ATE237309T1 (de) | Arzneizubereitungen | |
DE50009295D1 (de) | Vernetzerfreie zubereitungen | |
DE19880842D2 (de) | Niedrigdosierte 15-Desoxyspergualin-Präparate | |
SI1105114T1 (en) | Nimesulide containing topical pharmaceutical compositions | |
SE9800052D0 (sv) | Pharmaceutical compositions | |
SE9800330D0 (sv) | Pharmaceutical compositions | |
FI981567A0 (fi) | Farmaseuttiset koostumukset |